A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Grant

Date/time Interval

  • October 1, 2017 - September 30, 2022
  • Total Award Amount

  • 593008.00
  • Direct Costs

  • 456160.00
  • Sponsor Award Id

  • Contributor

  • Antonio Di Stasi M.D.   Principal Investigator  
  • Donna Salzman M.D.   Investigator  
  • Luciano Costa M.D., Ph.D.   Investigator  
  • Racquel Innis-Shelton M.D.   Investigator  
  • Ravi Bhatia M.D.   Investigator